Summary：**Scientists Engineer Bacteria to Target and Destroy Cancer Cells, Offering New Hope***Researchers a

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

**Scientists Engineer Bacteria to Target and Destroy Cancer Cells, Offering New Hope**

*Researchers are working to engineer bacteria that can kill cancerous tumours while reducing harm to healthy cells and tissue.*

---

### Introduction
A breakthrough in synthetic biology is shifting the cancer‑treatment paradigm. Scientists from several leading universities have reprogrammed harmless strains of *E. coli* and *Salmonella* to seek out malignant tissue, release cytotoxic agents, and then self‑destruct once the tumor is cleared. Early pre‑clinical models show tumor shrinkage of up to 70 % with minimal collateral damage to surrounding organs. The approach combines the natural tumor‑homing ability of certain microbes with precision genetic circuits, offering a potential alternative—or complement—to chemotherapy and immunotherapy.

### Key Developments
The latest study, published in *Nature Biotechnology*, details a two‑stage safety switch. First, bacteria are equipped with a tumor‑specific promoter that activates only in the low‑oxygen, acidic microenvironment typical of solid tumors. Second, a synchronized lysis circuit triggers bacterial death after a set number of replication cycles, limiting prolonged exposure. In mouse models of colorectal and breast cancer, the engineered microbes delivered payloads such as tumor‑necrosis factor‑α (TNF‑α) and a modified version of the toxin payload from *Pseudomonas aeruginosa*. Imaging confirmed bacterial accumulation exclusively within neoplasms, while blood tests revealed no systemic toxicity. Researchers also incorporated a kill‑switch responsive to an exogenous small molecule, providing clinicians an external “off‑switch” if needed.

### Industry Analysis
Biotech investors are taking note. Funding for microbial‑based oncology platforms rose 42 % year‑over‑year, with several start‑ups securing Series A rounds exceeding $80 million. Established pharmaceutical firms are exploring partnerships to